Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Celltrion just completed the phase 3 trial for its COVID-19 antibody treatment and it has shown very positive results. The biopharmaceutical company headquartered in Incheon, South Korea proves the efficacy of its treatment and full phase 3 results will follow before this month ends.
Outcome of phase 3 tests for the new COVID-19 antibody treatment
Celltrion said on Monday, June 14, that phase 3 of the clinical study for its Rekirona, yielded good results. This means that it was proven to be safe and effective after being tested with volunteer patients from 13 countries worldwide.
As per The Korea Herald, 1,315 patients took part in the third phase trial for Rekirona or CT-P59. The tests were conducted between the months of January and April of this year.
The South Korean biotech company stated that the treatment is effective and significantly reduced the recovery time and rate of progression for acute symptoms of COVID-19. Celltrion discovered through the phase 3 trial that the risk of cases progressing to a severe condition of coronavirus infection was reduced by 70%. In the high-risk group of patients, the progression rate to severe stage was said to have been cut by 72%.
What’s more, those treated with Celltrion’s Rekirona also showed significant results in recovery time as it was shortened. It was said that recovering from the disease was 4.7 to 4.9 days faster compared to others who used other treatments, Yonhap News Agency reported.
Most importantly, it was reported that the Celltrion COVID-19 antibody treatment did not show any serious adverse reaction. Only mild and temporary reactions were noted on the patients during the trial.
Celltrion’s shares surge after Celltrion’s phase 3 trial results were announced
Meanwhile, Pulse News reported that Celltrion’s shares increased by 5.08 percent to ₩279,000 or around $249.69 after the phase 3 test results for Rekirona were revealed. Celltrion Pharm, the company’s drug developing unit’s shares also went up by 12.54 percent to ₩156,200 while Celltrion Healthcare’s shares surged to 5.02 percent to ₩123,500.
In any case, Celltrion will now use the good results to seek marketing approval for the Covid-19 therapy in the U.S. The company will submit the documents to the U.S. Food and Drug Administration and the European Medicines Agency so it can be allowed to sell the treatment in the said regions.
